Am J Clin Nutr July 2013 ajcn.054445
Fatimah M Yousef, Elizabeth T Jacobs, Paul T Kang, Iman A Hakim,
Scott Going, Jehad M Yousef, Rajaa M Al-Raddadi, Taha A Kumosani, and Cynthia A Thomson cthomson at E-mail.arizona.edu
From the Department of Nutritional Sciences (FMY, CAT, and SG), the Mel and Enid Zuckerman College of Public Health (ETJ, IAH, PTK, and CAT), and the Arizona Cancer Center (CAT, ETJ, and IAH), University of Arizona, Tucson, AZ; the Faculty of Science for Girls (TAK and JMY) and the Faculty of Science (TAK and JMY), Department of Biochemistry, King Abdulaziz University, Jeddah, Saudi Arabia; and the Center of Excellence for Osteoporosis Research, Jeddah, Saudi Arabia (RMA).
This analysis of the de-identified data for epidemiological study was determined to be exempt according to regulations by the Human Subjects Committee at the University of Arizona.
Supported by the Ministry of Higher Education, Saudi Arabia, and King Fahd Center for Medical Research and performed under the Institutional Review Board at The King Fahd Medical Center.
Background: The role of vitamin D in breast cancer prevention is equivocal. Saudi Arabian women may be at greater risk of vitamin D deficiency because of a darker skin type and a greater likelihood of reduced ultraviolet B radiation exposure. Data regarding the vitamin D status of Saudi Arabian women and its relation to breast cancer risk are lacking.
Objective: The purpose of this research was to evaluate the association between circulating concentrations of 25-hydroxyvitamin D [25(OH)D] and breast cancer risk in Saudi Arabian women.
Design: A case-control study was conducted among 120 breast cancer cases and 120 controls. The study population was drawn from patients admitted to King Fahd Hospital in Jeddah, Saudi Arabia, from June to August 2009. Participants completed questionnaires on diet and medical history, and serum samples were collected from all women to measure circulating 25(OH)D concentrations.
Results: The participants had a mean age of 47.8 y and a mean body mass index (BMI; in kg/m2) of 30.0. Breast cancer cases had significantly lower (mean ± SD) serum concentrations of 25(OH)D (9.4 ± 6.4 ng/mL) than did controls (15.4 ± 12.3 ng/mL; P = 0.001). In comparison with those in the highest category of vitamin D status for this population (≥20 ng/mL), the adjusted ORs (95% CIs) for invasive breast cancer were 6.1 (2.4, 15.1) for women with a serum 25(OH)D concentration <10 ng/mL and 4.0 (1.6, 10.4) for women with a serum concentration of ≥10 to <20 ng/mL (P-trend = 0.0001).
Conclusion: An inverse association exists between serum 25(OH)D concentrations and breast cancer risk in Saudi Arabian women. This trial was registered at clinicaltrials.gov as NCT01817231.
Received November 12, 2012. Accepted April 4, 2013.
- 4X less Breast Cancer if have enough vitamin D – Dec 2010
- Breast Cancer survival 2X more likely if vitamin D sufficient – meta-analysis May 2013
- Breast Cancer and Vitamin D: Dr Garland - video June 2013
- Vitamin D Might Be Able to Slash Your Breast Cancer Risk by 90 Percent - Baggerly, Mercola: May 2013
- All items in Cancer - Breast
- Vitamin D and breast cancer – overview – Oncologist 2012
- Breast Cancer chance decreased 16 percent for every extra ng of vitamin D – Jan 2013
- Not enough women willing to stop taking vitamin D to permit breast cancer clinical trial – June 2012
- Breast tumor 1 inch bigger for each 1 ng decrease in vitamin D – Dec 2011
- 85 percent less risk of death from Breast Cancer when vitamin D levels higher than 30 ng – May 2012
In the UK: To minimize the possibility of breast cancer
take drugs with 18X less benefit, and huge number of side effects
6X less Breast Cancer if have even minimal vitamin D – July 2013
- Breast Cancer: NHS Should Offer Women With Family History Preventive Drugs Medical News today, June 2013
488,000 UK women will be eligible to take tamoxifen or raloxifene (both of which have 20+ side affects)
evidence indicates that tamoxifen or raloxifene will reduce chance of breast cancer by 1/3 X
vs vitamin D reduces chance of breast cancer by 6X and has no side effects
Cost is about 12X higher: 90 days: $24 tamoxifen, $2 Vitamin D (50,000 IU capsules)
4401 visitors, last modified 26 Jun, 2013,